Rosen Ted, Doherty Christy
Departments of Dermatology, Baylor College of Medicine and Veterans Affairs Medical Center Houston, Texas, USA.
Dermatol Online J. 2007 Jul 13;13(3):14.
A clinically refractory case of cutaneous sarcoidosis was successfully treated with infliximab infusion therapy at a dose of 5mg/kg. Skin lesions cleared dramatically and remain resolved during a 3(1/2) year follow-up, the longest follow-up reported to date. Ongoing biological drug therapy has been administered at a frequency of every 8-10 weeks. Despite cost and safety concerns, infliximab should be considered in cases of cutaneous sarcoidosis refractory to standard treatment protocols.
一例临床难治性皮肤结节病患者接受了剂量为5mg/kg的英夫利昔单抗输注治疗，取得了成功。皮肤病变显著消退，在3年半的随访期内一直保持缓解状态，这是迄今为止报道的最长随访时间。目前生物药物治疗的给药频率为每8 - 10周一次。尽管存在成本和安全问题，但对于标准治疗方案难治的皮肤结节病病例，应考虑使用英夫利昔单抗。
